Sartorius AG ADR

Sartorius AG ADR

SOAGY
Sartorius AG ADRUS flagOther OTC
57.12
USD
+0.87
- -
83.46BMarket Cap
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
2.32
2.61
3.27
3.8
4.11
4.58
5.34
6.83
10.08
12.2
9.93
9.8
10.25
7.89
Basic EPS, GAAP
0.15
0.14
0.37
0.3
0.34
0.41
0.46
0.61
0.93
1.98
0.6
0.24
0.45
0.62
Free Cash Flow per Basic Share
0.3
0.38
0.37
0.5
0.6
0.72
1.1
1.5
2.55
2.15
0.86
1.64
1.14
1.13
Dividend per Share
0.05
0.05
0.07
0.08
0.09
0.1
0.12
0.07
0.14
0.25
0.29
0.15
0.15
0.15
Book Value per Share
5.39
5.84
7.57
8.48
9.03
10.83
11.85
15.08
18.42
29.08
30.22
40.05
39.2
40.88
Tangible Book Value per Share
-2.65
-2.25
-1.42
-2.27
-6.78
-4.72
-4.64
-17.42
-17.5
-14.79
-50.24
-39.17
-37.53
-35.56
Basic Weighted Avg Shares
341
341
341
342
342
342
342
342
342
342
342
345
345
347
Sales/Revenue/Turnover
792
891
1,115
1,300
1,405
1,566
1,827
2,336
3,449
4,175
3,396
3,381
3,538
2,738
Operating Margin (%)
14.65
14.6
18.99
19.05
18.72
19.2
19.89
21.89
27.06
27.29
16.02
12.93
16.09
17.82
Depreciation Expense
48
55
59
76
98
113
133
180
231
287
342
416
420
320
Net Income, GAAP
52
48
126
103
115
141
157
210
319
678
206
84
155
215
Effective Tax Rate (%)
30.71
33.65
31.9
28.96
20.81
27.05
27.85
29.47
36.12
22.73
24.85
26.45
31.6
31.87
Profit Margin (%)
6.62
5.44
11.33
7.92
8.17
9.03
8.58
9
9.25
16.24
6.05
2.48
4.38
7.86
Working Capital
146
187
206
223
278
273
188
338
250
220
627
669
-201
199
LT Debt
369
379
366
452
887
895
881
1,892
1,738
1,986
5,023
4,167
3,356
3,648
Total Equity
450
498
645
737
807
973
1,093
1,380
1,720
2,659
2,758
3,898
3,867
3,998
Return on Invested Capital (%)
9.79
9.67
14.47
14.64
13.26
11.37
12.23
12.36
15.65
18.53
5.93
3.79
4.59
3.98
Return on Capital (%)
5.29
4.33
10.47
5.81
5.36
5.12
5.14
4.84
6.28
10.46
3.46
2.01
2.39
3.4
Return on Common Equity (%)
14.94
12.67
27.59
18.76
19.16
20.81
20.21
22.81
27.83
41.73
10.13
3.48
5.66
7.86

Capital Structure

FRC

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
926
964
404
LT Borrowings
3,184
3,169
3,487
LT Finance Leases
172
168
162
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
69
69
69
Market Capitalization
3,414
2,968
3,168

Working Capital

FRC

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
1,766
1,923
1,643
Cash, Cash Equivalents & STI
552
600
307
Accounts Receivable, Net
225
304
306
Inventories
792
827
832
Total Current Liabilities
1,967
2,113
1,444
Payables & Accruals
- -
- -
- -
ST Debt
926
964
404
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
20.65%
24.7%
-0.78%
Free Cash Flow
22.27%
11.45%
-30.23%
Net Income, GAAP
18.11%
24%
84.4%
Sales/Revenue/Turnover
13.49%
10.85%
4.66%
Total Cash Common Dividend
16.23%
28.58%
0.2%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
820
861
794
907
3,381
2025
883
884
- -
928
3,538
2026
899
912
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.11
0.07
0.02
- -
0.24
2025
0.14
0.09
- -
- -
0.45
2026
0.16
0.19
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
0.15
2025
- -
- -
- -
- -
0.15
2026
0.15
- -
- -
- -
- -

Company Description

CEO
Michael Grosse
Full Time Employees
14,042
Sector
Healthcare
Industry
Medical - Instruments & Supplies
Address
Otto-Brenner-Strasse 20 Göttingen NI Germany 37079
IPO Date
Aug 15, 2024
Business
Sartorius AG (SOAGY) is a leading international partner for biopharmaceutical research and the industry, providing innovative laboratory and process technology solutions. The company offers a broad portfolio of products and services including laboratory balances and pipettes under the Sartorius brand; filtration and purification systems such as Sartopore filters and Sartobind membranes; single-use bioreactor systems like the Biostat STR; bioprocess containers and assemblies; cell line development tools including ambr mini bioreactors; and process analytical technology solutions like Octet SPR systems; as well as services for bioprocess development, validation, and scale-up support. Sartorius operates in two main divisions: Sartorius Bioprocess Solutions, which focuses on tools for upstream and downstream bioprocessing, and Sartorius Lab Instruments and Services, serving research and quality control labs. The company serves biopharmaceutical manufacturers, research institutions, and industrial labs worldwide, with manufacturing sites and sales offices across Europe, North America, Asia-Pacific, and Latin America; it was founded in 1870 and is headquartered in Göttingen, Germany. In recent developments, Sartorius AG completed the acquisition of Danaher's Cytiva business in 2023, significantly expanding its bioprocess portfolio with complementary technologies in chromatography and filtration. The company launched the Sartorius Sartobrew tubes in 2024 for large-scale microbial fermentation and introduced the iQue advanced flow cytometry platform following the 2023 acquisition of IntelliCyt. Additionally, Sartorius formed strategic partnerships, including a collaboration with Roche in 2025 for process intensification in antibody production, and announced expansions in single-use bag production capacity in Germany and Singapore to meet growing demand in cell and gene therapy markets. These moves underscore Sartorius' focus on accelerating bioprocessing innovation amid rising global demand for biologics and personalized medicines.

Company News

  • Sartorius Aktiengesellschaft (OTCMKTS:SOAGY) Stock Short Interest Rises 322.6%

  • Sartorius Aktiengesellschaft (SOAGY) Q2 2026 Earnings Call Transcript

  • Sartorius Aktiengesellschaft (OTCMKTS:SOAGY) Short Interest Update

  • Sartorius Aktiengesellschaft (SOAGY) Q3 2025 Earnings Call Transcript